经济观察网阿斯利康于2026年2月10日发布2025年全年财报，总营收达587.39亿美元，同比增长8%；其 中肿瘤板块收入256.19亿美元，同比增长14%，占总营收44%。公司2025年第四季度营收155.03亿美 元，符合市场预期，核心营业利润41.00亿美元，主因研发投入加码。2026年业绩指引预计收入中高个 位数增长，核心盈利双位数增长，研发投入占比维持约24%。 财报分析 阿斯利康于2026年2月10日发布2025年全年财报，总营收达587.39亿美元，同比增长8%；其中肿瘤板块 收入256.19亿美元，同比增长14%，占总营收44%。公司2025年第四季度营收155.03亿美元，符合市场 预期，核心营业利润41.00亿美元，主因研发投入加码。2026年业绩指引预计收入中高个位数增长，核 心盈利双位数增长，研发投入占比维持约24%。 近期事件 战略合作：2026年2月10日，阿斯利康与中国石药集团达成潜在价值185亿美元的合作，获得长效肽技术 平台，布局GLP-1减肥药物市场。 研发进展：在2026年摩根大通医疗健康大会上，公司披露37个后期适应症拓展项目，重点包括靶向 CLDN18.2的ADC药 ...

Core Insights - Novo Nordisk's stock experienced a nearly 5% increase, influenced by the results of a competitor's clinical trial rather than its own performance [1][2] - Eli Lilly reported results from a phase 3 trial of orforglipron, an oral GLP-1 drug targeting weight loss, which showed an average body weight loss of nearly 12% over 72 weeks [3][5] - The weight loss results from orforglipron were perceived as underwhelming compared to expectations and Novo Nordisk's Wegovy, contributing to a positive market reaction for Novo Nordisk [5][8] Company Performance - Novo Nordisk's share price rose significantly, contrasting with the S&P 500 index's modest 0.8% increase on the same day [2] - The competitive landscape for GLP-1 weight loss drugs remains tight, with Novo Nordisk benefiting from Eli Lilly's trial results being less favorable than anticipated [8] Industry Context - The GLP-1 weight loss drug market is currently dominated by a duopoly, primarily involving Novo Nordisk's Wegovy and Eli Lilly's Zepbound, making any competitive advantage significant [8] - Eli Lilly's CEO expressed satisfaction with the trial results, emphasizing the convenience and scalability of orforglipron, despite the lower-than-expected weight loss results [6]